Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways.

@article{Seki2010BortezomibSH,
  title={Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways.},
  author={N Seki and Uhi Toh and Thomas Joseph Sayers and Teruhiko Fujii and Motoshi Miyagi and Yoshito Akagi and Jingo Kusukawa and Masayoshi Kage and Kazuo Shirouzu and Hideaki Yamana},
  journal={Molecular cancer therapeutics},
  year={2010},
  volume={9 6},
  pages={1842-51}
}
Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive human cancers, and novel treatment modalities are required. We investigated the therapeutic potential of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) in combination with the proteasome inhibitor bortezomib (Velcade) on human ESCC cell lines. Bortezomib… CONTINUE READING